19 August 2015_PR_IASLC curtain raiser_ENG
Category: Press release
Transgene plans restructuring to focus on research and development
20150629 PR 29 juin fin
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
20150601 PR TG4010 TIME results_ASCO 2015_FINAL
Transgene Announces Participation at Upcoming Investor Events
20150518 May thru July 2015 IR events_ver 1 ENG
Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
20150423 – US – EASL2015 TG1050
Transgene Reports First Quarter 2015 Financial Results
20150422 PR US Q1 2015
Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
20150421 AACR 2015_English
Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
20150416 SPA release version EN clean
Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
20150324 FY results 2014 full release_ENG FINAL
Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
18032015_AACR 2015 curtain raiser_EN